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A B S T R A C T
Background
The global tuberculosis epidemic results in nearly 2 million deaths and 9 million new cases of
the disease a year. The vast majority of tuberculosis patients live in developing countries, where
the diagnosis of tuberculosis relies on the identification of acid-fast bacilli on unprocessed
sputum smears using conventional light microscopy. Microscopy has high specificity in
tuberculosis-endemic countries, but modest sensitivity which varies among laboratories (range
20% to 80%). Moreover, the sensitivity is poor for paucibacillary disease (e.g., pediatric and HIV-
associated tuberculosis). Thus, the development of rapid and accurate new diagnostic tools is
imperative. Immune-based tests are potentially suitable for use in low-income countries as
some test formats can be performed at the point of care without laboratory equipment.
Currently, dozens of distinct commercial antibody detection tests are sold in developing
countries. The question is ‘‘do they work?’’
Methods and Findings
We conducted a systematic review to assess the accuracy of commercial antibody detection
tests for the diagnosis of pulmonary tuberculosis. Studies from all countries using culture and/
or microscopy smear for confirmation of pulmonary tuberculosis were eligible. Studies with
fewer than 50 participants (25 patients and 25 control participants) were excluded. In a
comprehensive search, we identified 68 studies. The results demonstrate that (1) overall,
commercial tests vary widely in performance; (2) sensitivity is higher in smear-positive than
smear-negative samples; (3) in studies of smear-positive patients, Anda-TB IgG by enzyme-
linked immunosorbent assay shows limited sensitivity (range 63% to 85%) and inconsistent
specificity (range 73% to 100%); (4) specificity is higher in healthy volunteers than in patients in
whom tuberculosis disease is initially suspected and subsequently ruled out; and (5) there are
insufficient data to determine the accuracy of most commercial tests in smear microscopy–
negative patients, as well as their performance in children or persons with HIV infection.
Conclusions
None of the commercial tests evaluated perform well enough to replace sputum smear
microscopy. Thus, these tests have little or no role in the diagnosis of pulmonary tuberculosis.
Lack of methodological rigor in these studies was identified as a concern. It will be important to
review the basic science literature evaluating serological tests for the diagnosis of pulmonary
tuberculosis to determine whether useful antigens have been described but their potential has
not been fully exploited. Activities leading to the discovery of new antigens with
immunodiagnostic potential need to be intensified.
The Editors’ Summary of this article follows the references.
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Introduction
The burden of disability and death due to tuberculosis (TB)
is immense, with 8.8 million new cases of the disease and 1.6
million deaths estimated to have occurred in 2005 alone [1].
Although the incidence of TB is constant or falling in many
regions of the world, rates remain high in sub-Saharan Africa
as a consequence of the HIV epidemic [1,2]. The expansion of
DOTS, the centerpiece of the international TB partnership
control strategy, has resulted in improved case-detection
rates during the past several years; however, the majority of
DOTS programs in high-burden countries have fallen short of
the 2005 global target of 70% case detection of the most
infectious cases [1].
The vast majority of TB patients live in low- and middle-
income countries [2], where the diagnosis of TB disease relies
primarily on identification of acid-fast bacilli on unprocessed
sputum smears using a conventional light microscope.
Microscopy is highly specific for Mycobacterium tuberculosis in
TB-endemic countries [3,4]. Although microscopy has been
reported to have greater than 80% sensitivity for identifying
cases of pulmonary TB in some settings [5,6], the sensitivity of
the test has been lower and variable in other reports (range
20% to 80%) [4,7]. Moreover, sensitivity is poor for
paucibacillary disease (e.g., pediatric and HIV-associated
TB) [8,9], a major concern on account of the strong
association between HIV infection and smear negativity
[10,11]. This lack of sensitivity of the sole diagnostic test in
many parts of the world results in delays in diagnosis,
enabling the disease to progress and increasing the potential
for transmission of M. tuberculosis [5]. To ensure appropriate
care for patients and to improve control of the global TB
epidemic, simple, accurate, inexpensive, and, ideally, point-
of-care diagnostic tools for TB are urgently needed.
The relative importance of the different characteristics of a
diagnostic test depends upon the setting in which the test is
to be performed and the intended use of the results.
Technical simplicity, for example, is essential if a test is to
be used in a primary health-care clinic or basic health
laboratory in low-income countries. If test results are to be
used to exclude a diagnosis of TB in patients with respiratory
symptoms in TB-endemic countries, then tests with a high
sensitivity (high negative predictive value) are required even
if the test is only moderately specific. Excluding TB patients
from this group would then allow a more rigorous diagnostic
work-up to be performed on a smaller group of patients. On
the other hand, if a test is to be used to identify patients with
respiratory symptoms in endemic countries for anti-TB
treatment, a high specificity (high positive predictive value)
is required. In the latter case, high sensitivity would also be
desirable.
Immune-based tests would seem to offer the potential to
improve case detection as currently performed, as some of
the test formats (e.g., immunochromatographic test) are
suitable for resource-limited areas. The major advantages of
immune-based tests are their speed (results may be available
within hours) and simplicity compared with microscopy
[8,12]. The development of immune-based tests for the
detection of antibodies, antigens, and immune complexes
has been attempted for decades, and their performance has
been critically appraised in several descriptive reviews and
textbook chapters [13–22]. The most common of these tests
rely on detection of the humoral (serological) antibody
immune response to M. tuberculosis (the subject of this
systematic review), as opposed to the T cell–based cellular
immune response (e.g., interferon-gamma release assays), or
direct detection of antigens in specimens other than serum
(e.g., lipoarabinomannan [LAM] detection in urine [23,24]
and pleural fluid [25]).
A number of in-house antibody detection tests have been
developed but are not marketed. These tests use different
antigens and distinct protocols and techniques.
Currently, in developing countries, where diagnostic tests
are rarely subjected to regulatory review or approval [26,27],
test manufacturers and distributors are marketing dozens of
different antibody detection diagnostic commercial kits. The
extent of their use is largely unknown; however, companies
report sales volumes between 3,000 and 300,000 tests per year
[28]. These tests differ in a number of their features,
including antigen composition, antigen source (e.g., native
or recombinant), chemical composition (e.g., protein, carbo-
hydrate, or lipid), extent and manner of purification of the
antigen(s), and class of immunoglobulin detected (e.g., IgG,
IgM, or IgA). Performance data are often limited to those
found in the package inserts and, being based on small sets of
patients, are typically favorable (J. Cunningham, personal
communication).
An antibody detection test can be developed into a number
of formats depending on the membrane, antigen(s) coating,
and incubation technique. Common designs include the
enzyme-linked immunosorbent assay (ELISA) format and the
immunochromatographic test format. ELISA is a complex
assay with several steps: coating of antigens onto the surface
of plastic wells, the addition of serum samples to the wells,
and several washing stages. Antigen–antibody reactions are
visualized using anti-human antibody linked to an enzymatic
indicator system [29]. The assay can take hours to perform.
The immunochromatographic test is simpler. In this techni-
que, the antigens are pre-coated in lines across a membrane
(e.g., nitrocellulose) to which samples are applied. Antigen–
antibody reactions are visualized on the lines using anti-
human antibody bound to substances such as colloidal gold.
The test takes only a few minutes to perform [30].
The ELISA format has the advantages that many serum
samples can be tested in parallel and the process can be
completely automated, making this technique attractive in fully
equipped laboratories that test a large number of samples. For
developing countries with limited laboratory resources and
access, an immunochromatographic test would be the pre-
ferred method, as this format requires only visual inspection of
the antigen-containing lines and can, therefore, be performed
at the point of care without laboratory equipment.
An initial survey of the literature found more than 200
studies that have evaluated commercial serological antibody
detection tests, hereafter referred to as commercial tests, for
the diagnosis of pulmonary TB. To our knowledge, this vast
body of literature has not been systematically reviewed and
synthesized. We therefore conducted a systematic review to
summarize the evidence on accuracy (sensitivity and specificity)
of commercial tests, according to the guidelines and methods
proposed for diagnostic systematic reviews and meta-analyses
[31]. We specifically addressed two questions. (1) How accurate
are commercial tests for the diagnosis of pulmonary TB overall
and for smear-positive and smear-negative disease? (2) What is
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the specificity of commercial tests in healthy control partic-
ipants compared with the specificity in patients without TB, but
in whom TB was initially suspected?
Methods
Search Strategy
We searched electronic databases for primary studies:
PubMed (http: / /www.ncbi.nlm.nih.gov/entrez/query.
fcgi?DB¼pubmed) (1990 to May 2006), BIOSIS (http://
scientific.thomson.com/biosis/) (1990 to October 2005), Embase
(http://www.embase.com) (1990 to October 2005), and Web of
Science (http://scientific.thomson.com/products/wos/) (1990 to
October 2005). The search terms used included the following:
‘‘tuberculosis’’, ‘‘Mycobacterium tuberculosis’’, ‘‘immunological
tests’’, ‘‘serological tests’’, ‘‘antibody detection’’, ‘‘antigen
detection’’, ‘‘ELISA’’, ‘‘Western blot’’, and ‘‘sensitivity and
specificity’’. We identified additional studies by contacting
experts in the field and by searching reference lists from
primary studies, review articles, and textbook chapters.
Study Selection
Our search strategy sought to identify all available articles
published in English that evaluated commercial tests for the
serological diagnosis of pulmonary TB. We included only
those studies in which patients had bacteriologically con-
firmed pulmonary TB, and in which results were provided
separately for smear-positive and smear-negative patients. In
particular, we defined the reference standard as either
isolation of M. tuberculosis on culture, or, for studies
conducted without culture in endemic countries, the pres-
ence of acid-fast bacilli detected by sputum smear micro-
scopy. No restrictions were made with respect to study design
(cross sectional or case control) or data collection (prospec-
tive or retrospective).
We excluded studies that relied solely on clinical or
radiological features or improvement while on anti-TB
therapy as the criteria for establishing the diagnosis of TB.
In addition, the following studies were excluded: (1) studies
published before 1990, for the reason that many studies used
crude antigen extracts or obsolete immunological methods;
(2) studies with fewer than 50 participants (at least 25 TB
patients and 25 control participants were required for
inclusion); (3) studies of latent TB infection; (4) studies of
nontuberculous mycobacteria; (5) studies of antibody re-
sponses during or after TB treatment; (6) investigations
conducted using non-immunologic methods for detection of
antibodies; (7) basic science literature that focuses on cloning
of new antigens or their immunologic properties (e.g.,
epitope mapping) or other new methods of antibody
detection; and (8) case reports and reviews.
Initially, two reviewers (KRS and MH) screened citations
retrieved from all sources. To identify relevant studies
pertaining specifically to commercial tests, a second screen-
ing was done (KRS and MH) of full texts from citations found
to be relevant in the first screen. A list of excluded studies,
along with the reasons for exclusion, is available from the
authors on request.
Data Extraction
We created and piloted a data-extraction form with a
subset of eligible studies. Based upon experience gained in
the pilot, the data-extraction form was finalized. One
reviewer (KRS) extracted data from all eligible studies on
the following qualities: study design and methodological
quality (see assessment of study quality below), study
population, antigen and antibody characteristics, laboratory
technique, reference standard, and outcome data (sensitivity
and specificity). To verify reproducibility of data extraction, a
second reviewer (M. Henry) independently extracted data
from 15% of the included studies. The inter-rater agreement
between the two reviewers for sensitivity and specificity
estimates was 100%. When data were not clearly reported, the
information was coded as ‘‘not reported’’. When necessary,
we attempted to contact authors for additional information.
Although some authors compared performance of com-
mercial tests in several different groups without TB, we
preferentially selected only one comparison group (control
participants) for each study in the following order: (1)
patients in whom pulmonary TB was initially suspected but
who were later found to have nontuberculous respiratory
disease; (2) patients diagnosed with a variety of diseases other
than TB (mixed disease); (3) healthy persons from endemic
countries; (4) contacts of patients with TB; (5) mixed groups
from categories (1) to (4); and (6) healthy persons from non-
endemic countries. In our view, this hierarchy gave priority to
the populations expected to be encountered in a routine
clinical setting.
Assessment of Study Quality
We assessed the quality of studies using the following
criteria, which have been suggested as being important for
diagnostic studies [31]. (1) Was there a comparison of the
commercial test with an independent, appropriate reference
standard (i.e., the commercial test did not form part of the
reference standard)? (2) Was the commercial test result
performed and recorded by technicians who were unaware
(blinded) of the results of the reference standard? (3) Did the
whole sample or a randomly selected subset of the sample
receive verification using the reference standard? (4) Did the
study prospectively recruit consecutive patients suspected of
having pulmonary TB?
Data Collation and Meta-Analysis
We used standard methods recommended for meta-
analyses of diagnostic test evaluations [31,32]. As studies were
heterogeneous, particularly with respect to the antigen
composition of the tests, antibody class (IgG, IgM, or IgA),
comparison groups, and sputum status of the patients, we
first grouped studies by type of commercial test and then
further stratified by immunoglobulin class and smear status.
To calculate sensitivity and specificity values for the
commercial tests, we cross-tabulated each result against the
reference standard. Sensitivity refers to the proportion of
pulmonary TB patients with a positive result on a given
commercial test; specificity refers to the proportion of TB-
negative participants who had negative results on a given
commercial test. Whenever possible, we extracted raw data
from primary studies to fill the four cell values of a diagnostic
23 2 table: true positives, false positives, true negatives, and
false negatives. In calculations of sensitivity, we included
studies from endemic countries that used sputum smear
positivity as the reference standard along with studies using
culture as the reference standard. We recognized that some
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authors used the same comparison group for multiple studies,
and thus derived identical specificity estimates. Therefore, in
determining specificity, we included the specificity value for
the specific comparison group only once when appropriate.
For clarity of presentation, studies that reported results
stratified by subgroups are shown more than once in tables or
figures.
Data were analyzed using SPSS (version 14.0.1.366) [33] and
Meta-DiSc (version 1.4) software [34]. Sensitivity and specific-
ity values were calculated for the commercial tests inves-
tigated in each study, along with their 95% confidence
intervals (CIs). In addition to the sensitivity and specificity
estimates and forest plots generated for this review, true
positive rates (TPR¼ sensitivity) and false positive rates (FPR
¼ 1  specificity) were summarized using an asymmetric
summary receiver operating characteristic (SROC) curve [35].
TPR and FPR are not independent of each other as they vary
with the thresholds (cut points for determining test positives)
employed in the original studies. In addition, it is likely that
different thresholds were used in various studies, either
implicitly or explicitly. Because of the inherent trade-off
between TPR and FPR, it is imperative to plot the estimates of
the two quantities in a receiver operating characteristic
(ROC) space and to use meta-analytic methods that take into
account the threshold effect. Thus, we did not pool the
sensitivity and specificity estimates separately; instead we
analyzed TPR and FPR as pairs in an SROC analysis, and
explored the effect of variability in cut points on study
results.
Unlike a traditional ROC plot that explores the effect of
varying thresholds on sensitivity and specificity in a single
study, each data point in the SROC space represents an
individual study. As described by Littenberg and Moses [32],
the SROC analysis involves three steps: (1) the pairs of TPR
and FPR estimates from each study are transformed onto a
suitable scale of log odds; (2) a linear regression equation is
fitted using the transformed data; and (3) the coefficients
from the linear regression model are used to generate a curve
in the original ROC space.
The area under the curve (AUC) (in this case, being the area
under the SROC curve) presents an overall summary of test
performance and displays the trade-off between sensitivity
and specificity. An AUC of 1.0 (100%) indicates perfect
discriminatory ability of the diagnostic test. In addition, the
Q* index is another useful global estimate of test accuracy for
comparing SROC curves. The Q* index, defined by the point
Figure 1. Flow Diagram for Study Selection
doi:10.1371/journal.pmed.0040202.g001
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where sensitivity equals specificity on the SROC curve, is the
point on the SROC curve that is intersected by the anti-
diagonal. A Q* value of 1.0 indicates 100% accuracy
(sensitivity and specificity of 100%) [32,35,36].
In meta-analyses of studies of diagnostic tests, heteroge-
neity refers to a high level of variability in study results [37].
Such heterogeneity could be a result of variability in
thresholds, laboratory technique, disease spectrum, study
design, and/or quality between studies [37]. In the presence of
significant heterogeneity, pooled or summary estimates from
meta-analyses are hard to interpret. Given the anticipated
variability in accuracy, we decided, a priori, to avoid direct
pooling of sensitivity and specificity values. Also, as described
earlier, we addressed heterogeneity by using subgroup
(stratified) analyses.
Results
Description of Included Studies
From the literature searches, we identified 3,720 citations,
of which 27 publications (68 studies) met our eligibility
criteria (Figure 1) [38–64]. We considered most studies to be
distinct ([43], study b, is a substudy). Therefore, no effort was
made to account for lack of independence. Of the total 68
studies, 32 (47%) collected data prospectively and 36 (53%),
retrospectively. Twenty-four (35%) studies used either ran-
dom or consecutive recruitment of participants, while 44
(65%) studies did not report the method of participant
selection. Thirty-one (46%) studies reported at least single-
blinded interpretation of commercial test and reference
standard results. Mycobacterial culture was used as the gold
standard in 51 (75%) studies and sputum smear microscopy
was used in 17 (25%) studies. For all studies, the commercial
test did not form part of the reference standard. In 39 (57%)
studies, the entire study population was investigated using the
identical reference standard (complete verification), while in
18 (26%) studies, the reference standard for TB patients and
control participants differed (e.g., mycobacterial culture for
TB patients and chest radiograph for control participants
[differential verification]). For 11 (16%) studies, information
about verification was unclear or not reported. Seventeen
(25%) studies met all four criteria for good quality [43,48,53].
Forty-one (60%) studies were performed with smear micro-
scopy–positive patients, and 27 (40%) were conducted with
smear microscopy–negative patients. No studies involved
children younger than 15 y old or patients with HIV
infection. The median number of TB patients was 41
(interquartile range 38 to 75); the median number of control
participants in comparison groups was 45 (interquartile
range 40 to 107).
Antibody detection was done with stored, frozen sera in 59
(87%) studies and with fresh sera in one (2%) study [60]; in
eight (12%) studies, the condition of the specimens was not
reported. A total of nine different commercial tests are
included in the review. For seven (78%) commercial tests, the
specific antigen composition was described; for two (22%)
tests, the antigen composition was considered a proprietary
product. Fifty-nine (87%) studies assessed the performance of
individual commercial tests. Nine (13%) studies evaluated the
performance of two or more commercial tests used in
combination. In these nine studies, the commercial tests
(Pathozyme TB Complex Plus and Pathozyme Myco) cameTa
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Figure 2. Sensitivity Estimates of Commercial Tests for the Diagnosis of Pulmonary TB
The circles and lines represent the point estimates and 95% CIs, respectively. The size of the circle indicates the study size.
doi:10.1371/journal.pmed.0040202.g002
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from the same manufacturer, but differed in their antigen
composition and/or immunoglobulin class. Table 1 lists
selected characteristics of the commercial tests employed in
the review, together with the names and addresses of their
respective manufacturers.
How Accurate are Commercial Tests for the Diagnosis of
Pulmonary TB Overall and for Smear-Positive and Smear-
Negative Disease?
Tables 2–10 show performance and other selected charac-
teristics for the commercial tests in the review. When all 68
studies were considered together, the sensitivity estimates
ranged from 10% to 90% (Figure 2), and the specificity
estimates ranged from 47% to 100% (Figure 3). On the whole,
both measures varied widely among studies of a given
commercial test and in studies across different commercial
tests. Figure 4 shows performance for all commercial tests
combined in a SROC curve. The AUC was 0.89 (95% CI 0.86–
0.92), and the Q* index was 0.82, indicating modest accuracy.
The accuracy of commercial tests in patients with smear-
positive pulmonary TB was higher (AUC¼ 0.90, 95% CI 0.86–
0.94; 41 studies [Figure 5A]) than in patients with smear-
negative disease (AUC ¼ 0.84, 95% CI 0.77–0.91; 27 studies
[Figure 5B]). These differences were, however, not statistically
significant, based on overlapping CIs for the AUCs. Corre-
sponding forest plots of sensitivity and specificity are shown
in Figures S1–S4.
Anda-TB IgG was the test most frequently evaluated in the
review. Figure 6 shows the forest plots for studies using Anda-
TB IgG for the diagnosis of pulmonary TB in smear micro-
scopy–positive patients (ten studies) [38,40,41,51,52,56,59,
61,62,64]. Figure S5 shows the corresponding SROC curve.
Sensitivity values ranged from 63% to 85%, with sensitivity 
80% in four (40%) studies [38,51,62,64]; specificity values
ranged from 73% to 100%, with specificity , 90% in four
(40%) studies [52,61,62,64]. The AUC was 0.86 (95% CI 0.77–
0.95), which was lower than the value noted in studies of smear
microscopy–positive patients for all commercial tests com-
bined. In smear microscopy–negative patients (four studies)
[41,52,56,64], sensitivity estimates for Anda-TB IgG were low
and variable (64%, 71%, 73%, and 35%); corresponding
specificity estimates were similar (93%, 89%, 91%, and 88%)
(Table 2). After stratifying by smear status, there were fewer
than four studies for the other commercial tests. For each of
these studies, sensitivity and specificity values are shown in
Tables 2–10.
What is the Specificity of Commercial Tests in Healthy
Control Participants Compared with the Specificity in
Patients without TB, but in Whom TB was Initially
Suspected?
We determined specificity estimates for a subgroup of
studies involving healthy participants [40,42,44,45,57,63]
compared to patients in whom TB disease was initially
considered and subsequently ruled out (nontuberculous
respiratory disease) [38,39,41,46,47,49–56,58,60,61,64]. In
healthy volunteers, specificity values ranged from 86% to
100%, with seven (88%) studies [40,42,44,57,63] demonstrat-
ing specificity values higher than 90%. In comparison, in
studies of patients with nontuberculous respiratory disease
(23 studies), specificity values ranged from 47% to 100%;
specificity values were higher than 90% in only seven (30%)
studies [38,41,49,51,56] (Figure 7). Compared with studies
involving patients with nontuberculous respiratory disease,
studies in healthy volunteers showed a higher value for the
AUC (0.91 [95% CI 0.73–1.10] versus 0.87 [95% CI 0.82–0.92]),
although this difference was not statistically significant, based
on overlapping CIs (Figure S6A and S6B).
Discussion
Principal Findings
Our systematic review of 68 studies examining the
performance of commercial tests for the diagnosis of
pulmonary TB suggests that (1) overall, commercial tests vary
widely in performance; (2) sensitivity is higher in smear-
positive than smear-negative samples; (3) in studies of smear-
positive patients, Anda-TB IgG by ELISA shows limited
sensitivity (range 63% to 85%) and inconsistent specificity
(range 73% to 100%); (4) specificity is higher in healthy
volunteers than in patients in whom TB disease is initially
suspected and subsequently ruled out; and (5) there are
insufficient data to determine the accuracy of most commer-
cial tests in smear-negative patients, as well as their perform-
ance in children or persons with HIV infection.
Our systematic review had several strengths. First, the
comprehensive search strategy with various overlapping
approaches enabled us to retrieve relevant studies published
since 1990. Moreover, two reviewers independently com-
pleted screening and study selection. To verify reproduci-
bility of data extraction, a second reviewer independently
extracted data on sensitivity, specificity and study quality in
15% of the included studies. We contacted authors for
missing data. None of the studies in the review used the result
from the antibody test as a reference to confirm TB
(incorporation bias). When possible, we selected studies using
patients with disease, in preference to healthy control
participants, to evaluate how well antibody tests performed
in patients with and without pulmonary TB among persons
suspected of having TB. Finally, we analyzed data within
specific subgroups to lessen the effect of heterogeneity.
This review also had limitations. Except for Anda-TB IgG,
there were not sufficient relevant studies for specific
commercial tests to provide meaningful summary measures
of performance, particularly in smear-negative samples. In
addition, there were no studies that met our inclusion criteria
for the diagnosis of pulmonary TB in children or in patients
with HIV infection. Another problem concerned limited
information on clinical status and disease severity in the
populations tested. Differing criteria for patient selection
and greater duration and severity of illness of the study
populations may have introduced significant variability in
findings among studies (selection bias). Moreover, different
settings (e.g., areas of high HIV prevalence, hospitals, and out-
patient clinics) may have accounted for some of the observed
variation in test performance. The condition of specimens
may have affected the sensitivity results. Only one study [60]
used fresh serum; the vast majority (87%) of studies used
frozen sera; thus samples were subjected to an unknown
freeze–thaw cycle history, which may decrease sensitivity [58].
A majority (75%) of studies used mycobacterial culture as the
reference standard. Although in TB diagnostic trials, myco-
bacterial culture is considered the gold standard, culture does
not detect all cases of TB; therefore, some degree of
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Figure 3. Specificity Estimates of Commercial Tests for the Diagnosis of Pulmonary TB
The circles and lines represent the point estimates and 95% CIs, respectively. The size of the circle indicates the study size.
doi:10.1371/journal.pmed.0040202.g003
PLoS Medicine | www.plosmedicine.org June 2007 | Volume 4 | Issue 6 | e2021053
Antibody Detection for Pulmonary TB
misclassification of disease for study participants was possi-
ble. We included studies from endemic countries that used
sputum smear microscopy, a test with modest sensitivity (up
to 70%–80%), as the reference standard; use of an insensitive
reference standard may have led to biased estimates of
commercial test accuracy [65]. The choice of the reference
standard (culture and/or smear) for this review was a problem
for pediatric TB. In this group, it is difficult to diagnose
pulmonary TB on the basis of bacteriologic confirmation [9].
Another set of problems involved shortcomings in study
design and quality. Only 24 (35%) studies recruited partic-
ipants in a random or consecutive manner. Therefore, most
studies lacked the sound probabilistic sampling framework
possible in consecutive or random sampling designs. Only
approximately half of the studies (31 [46%]) reported blinded
interpretation of the results of the commercial test and the
reference standard, a major limitation of the currently
available literature. Lack of blinding may have resulted in
an overestimation of the sensitivity of the commercial test
result [66]. In 29 (43%) studies, different diagnostic tests were
performed in TB patients and control participants (myco-
bacterial culture for patients and chest radiographs for
control participants [verification bias]), or information about
the tests to rule out TB, if performed, was not reported. Only
17 (25%) studies met all four criteria for good quality.
Variability in study design and study quality might account
for some of the observed heterogeneity evident in the results.
Although statistical tests and graphical methods are available
to detect potential publication bias in meta-analyses of
randomized trials, such techniques have not been adequately
evaluated for diagnostic data [67]. Thus, it is difficult to rule
out publication bias in our review. In addition, our search
strategy may have missed some relevant studies by excluding
non-English publications. This represented approximately
20% of all excluded studies.
Finally, because the antigen content of commercial tests is
sometimes considered proprietary information, we could not
determine the antigen composition for all tests in the review.
Test manufacturers may change their product without
forewarning and, in some countries, such as Brazil, products
are registered in the distributor’s name; a change in
distributor will therefore result in a change in product name,
making it difficult to ascertain which tests are in current use.
These points argue for independent evaluations of new
immune-based diagnostic tests and, by extension, greater
regulatory oversight of diagnostic tests in general, partic-
ularly for diseases that have a significant public health
impact.
Despite the long history of failed attempts to develop an
accurate serodiagnostic test for TB and the inadequate
performance of the current commercial tests, it is important
to emphasize that studies during the past decade have not
only permitted an understanding of the lacunae in the efforts
so far [19,20,68,69], but have also identified several promising
candidate antigens [19,20,68–73]. A systematic analysis of the
humoral immune responses of TB patients has shown that the
profile of antigenic proteins of M. tuberculosis recognized by
antibodies differs at different stages of infection and disease
progression [68,69,74,75] and thus, an accurate diagnostic test
for TB will need to be based on a combination of antigens
[68,69,75]. In HIV-infected TB patients, several antigens that
are recognized by antibodies have been delineated, however,
Figure 4. SROC Curve of Commercial Tests for the Diagnosis of Pulmonary TB
Each solid circle represents an individual study in the meta-analysis. The curve is the regression line that summarizes the overall diagnostic accuracy. SE
(AUC), standard error of AUC; Q*, an index defined by the point on the SROC curve where the sensitivity and specificity are equal; SE (Q*), standard error
of Q* index.
doi:10.1371/journal.pmed.0040202.g004
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Figure 5. SROC Curve of Commercial Tests for the Diagnosis of Pulmonary TB
(A) Smear microscopy–positive patients; (B) smear microscopy–negative patients. Each solid circle represents an individual study in the meta-analysis.
The curve is the regression line that summarizes the overall diagnostic accuracy. SE (AUC), standard error of AUC; Q*, an index defined by the point on
the SROC curve where the sensitivity and specificity are equal; SE (Q*), standard error of Q* index.
doi:10.1371/journal.pmed.0040202.g005
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only the 81-kDa malate synthase protein has been evaluated
in patients from different countries [19,20,70–73]. It is
encouraging that this antigen provided equivalent sensitivity
in patients from India, the United States, and Uganda
[19,20,70] since it has been suggested that differences in
genetic make-up might account for the observed variations in
antibody responses to specific M. tuberculosis antigens [13,76].
Antigens that are immunodominant during extrapulmo-
nary and pediatric TB also need to be identified. A systematic
review of 21 studies evaluating the performance of commer-
cial tests for the diagnosis of extrapulmonary TB showed
highly variable estimates of sensitivity and specificity, and no
studies were of sufficient quality to enable their evaluation in
patients with HIV infection or in children—the two groups
for which the test would be most useful [77].
Conclusions and Policy Implications
The evidence provided in this systematic review suggests
that, at this point in time, published data on commercial
antibody detection tests produce inconsistent estimates of
accuracy, and none of the assays perform well enough to
replace sputum smear microscopy. These tests thus have little
or no role to play in the diagnosis of pulmonary TB at the
present time. Given these findings, we express concern that
commercial tests in present use may divert resources in
developing countries away from smear microscopy. Our
findings underscore the need for greater regulatory oversight
of in vitro diagnostics and improved capacity in countries to
design, conduct, and report diagnostic test evaluations which,
in turn, can guide procurement and clinical practice. Lack of
methodological rigor in these studies was a cause for concern.
Recent articles have attested to the mediocre quality of
diagnostic studies for TB [26,78]. Use of guidelines such as the
Standards for Reporting of Diagnostic Accuracy (STARD)
[79] and the tool for quality assessment of diagnostic accuracy
studies (the QUADAS tool) [80] may lead to improvements in
the quality of future studies. Guidelines specifically for the
evaluation of diagnostic tests for infectious diseases have
recently been published [81].
It is important that the literature from research laborato-
ries that have evaluated the immunodiagnostic potential of
different antigens be reviewed to determine whether there
are useful antigens which have been described but whose
potential has not been fully exploited. The increased under-
standing of the humoral immune responses in TB patients
and the new tools of genomics and proteomics could well lead
Figure 6. Sensitivity and Specificity Estimates of Anda-TB IgG for the Diagnosis of Pulmonary TB, Smear Microscopy–Positive Patients
(A) Sensitivity; (B) specificity. The circles and lines represent the point estimates and 95% CIs, respectively. The size of the circle indicates the study size.
doi:10.1371/journal.pmed.0040202.g006
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to devising the simple, rapid, and accurate serodiagnostic test
that that has eluded us so far. Activities aimed at discovering
new antigens with immunodiagnostic potential need to be
intensified. Trials of new serodiagnostic tests for pulmonary
TB must adequately address the particular challenges
presented by smear microscopy–negative patients, children,
and persons with HIV infection.
Supporting Information
Figure S1. Sensitivity Estimates of Commercial Tests for the Diagnosis
of Pulmonary TB, Smear Microscopy–Positive Patients
The circles and lines represent the point estimates and 95% CIs,
respectively. The size of the circle indicates the study size. Numbers in
parentheses indicate references. EIA, enzyme immunoassay; IgG, IgM,
IgA (G, M, A), immunoglobulin G, M, A, respectively; KAT, kaolin
agglutination test; P Plus, Pathozyme TB Complex Plus; Path,
Pathozyme; TBGL, tuberculosis glycolipid assay.
Found at doi:10.1371/journal.pmed.0040202.sg001 (262 KB PDF).
Figure S2. Specificity Estimates of Commercial Tests for the
Diagnosis of Pulmonary TB, Smear Microscopy–Positive Patients
The circles and lines represent the point estimates and 95% CIs,
respectively. The size of the circle indicates the study size. Numbers in
parentheses indicate references. EIA, enzyme immunoassay; IgG, IgM,
IgA (G, M, A), immunoglobulin G, M, A, respectively; KAT, kaolin
agglutination test; P Plus, Pathozyme TB Complex Plus; Path,
Pathozyme; TBGL, tuberculosis glycolipid assay.
Figure 7. Specificity Estimates of Commercial Tests
(A) Healthy control participants; (B) patients with nontuberculous respiratory disease. Studies using identical comparison groups appear only once. The
circles and lines represent the point estimates and 95% CIs, respectively. The size of the circle indicates the study size.
doi:10.1371/journal.pmed.0040202.g007
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Found at doi:10.1371/journal.pmed.0040202.sg002 (257 KB PDF).
Figure S3. Sensitivity Estimates of Commercial Tests for the Diagnosis
of Pulmonary TB, Smear Microscopy–Negative Patients
The circles and lines represent the point estimates and 95% CIs,
respectively. The size of the circle indicates the study size. Numbers in
parentheses indicate references. EIA, enzyme immunoassay; IgG, IgM,
IgA (G, M, A), immunoglobulin G, M, A, respectively; KAT, kaolin
agglutination test; P Plus, Pathozyme TB Complex Plus; Path,
Pathozyme; TBGL, tuberculosis glycolipid assay.
Found at doi:10.1371/journal.pmed.0040202.sg003 (259 KB PDF).
Figure S4. Specificity Estimates of Commercial Tests for the
Diagnosis of Pulmonary TB, Smear Microscopy–Negative Patients
The circles and lines represent the point estimates and 95% CIs,
respectively. The size of the circle indicates the study size. Numbers in
parentheses indicate references. EIA, enzyme immunoassay; IgG, IgM,
IgA (G, M, A), immunoglobulin G, M, A, respectively; KAT, kaolin
agglutination test; P Plus, Pathozyme TB Complex Plus; Path,
Pathozyme; TBGL, tuberculosis glycolipid assay.
Found at doi:10.1371/journal.pmed.0040202.sg004 (256 KB PDF).
Figure S5. SROC Curve of Anda-TB IgG for the Diagnosis of
Pulmonary TB, Smear Microscopy–Positive Patients
Each solid circle represents an individual study in the meta-analysis.
The curve is the regression line that summarizes the overall
diagnostic accuracy. SE (AUC), standard error of AUC; Q*, an index
defined by the point on the SROC curve where the sensitivity and
specificity are equal; SE (Q*), standard error of Q* index.
Found at doi:10.1371/journal.pmed.0040202.sg005 (234 KB PDF).
Figure S6. SROC Curve of Commercial Tests for the Diagnosis of
Pulmonary TB
(A) Healthy control participants; (B) patients with nontuberculous
respiratory disease. Each solid circle represents an individual study in
the meta-analysis. The curve is the regression line that summarizes
the overall diagnostic accuracy. SE (AUC), standard error of AUC; Q*,
an index defined by the point on the SROC curve where the
sensitivity and specificity are equal; SE (Q*), standard error of Q*
index.
Found at doi:10.1371/journal.pmed.0040202.sg006 (266 KB PDF).
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Editors’ Summary
Background. Tuberculosis (TB) is, globally, one of the most important
infectious diseases. It is thought that in 2005 around 1.6 million people
died as a result of TB. Controlling TB requires that the disease is correctly
diagnosed so that it can then be promptly treated, which will reduce the
risk of infection being passed on to other individuals. The method
normally used for diagnosing TB disease in poor countries (where most
people with TB disease live) involves taking a sample of mucus coughed
up from the lungs; this mucus is then spread thinly onto a glass slide,
dyed, and viewed under the microscope. The bacteria responsible for TB
take up the dye in a particular pattern and can be clearly seen under the
microscope. Although this test (sputum smear) is relatively straightfor-
ward to carry out even where facilities are basic, it is not particularly
good at identifying TB disease in children or amongst individuals who
are HIV-positive. Finally, the sputum smear test is also not very sensitive;
that is, many people who have TB disease may not give a positive
reading. Therefore, there is an urgent need to develop and evaluate new
tests that are suitable for use in poor countries, which will accurately
diagnose TB disease, especially amongst children and people who are
HIV-positive.
Why Was This Study Done? New tests for TB have become available
which detect whether an individual has raised antibodies against
particular proteins and other substances present on the surface of the
TB bacterium. These tests are carried out on blood samples, once blood
cells and other factors have been taken out. These antibody tests are
often quite simple to carry out, so in principle they could be suitable for
use in developing countries. Since the tests are available on the market
and can be freely used in some developing countries without any need
for government regulatory bodies to approve them, it is important to
know how good these tests are at diagnosing TB disease. The
researchers here wanted, therefore, to evaluate all of the available data
relating to the accuracy of antibody detection tests for diagnosis of TB
disease.
What Did the Researchers Do and Find? In order to evaluate all of the
information available on commercial antibody detection tests for
diagnosis of TB disease of the lungs, the researchers carried out a
systematic review. First, they searched biomedical literature databases
using specific terms to identify studies for inclusion. A study was
included in their analysis if the commercial test was compared against
one of two other standard tests (sputum smear microscopy, or growth of
TB bacteria in culture). One researcher from the team then pulled out
specific pieces of information from each published study: these included
the type of study design; information on study participants; the type of
test; what the test was compared against; and finally the results of
evaluation of the test. A second researcher pulled out pieces of
information from several of the same studies. The researchers then
compared the information to ensure that it was recorded correctly. Each
study was also assigned a quality rating, based on four distinct criteria.
For each type of test, the researchers used the data in the published
studies to work out the test’s accuracy, both in terms of its ability to give
a positive reading for people who have TB disease as well as its ability to
give a negative reading for people who do not have TB disease.
The researchers found 27 papers meeting their criteria. These papers
reported the results of 68 original studies. Nine different commercial
tests were examined in the studies. Overall, the studies seemed to be of
relatively poor quality, with only 25% of them meeting all four of the
researchers’ criteria for a good-quality study. The different studies
appeared to produce varying results for the accuracy of these
commercial tests. In particular, the tests seemed to be less accurate at
detecting TB disease amongst people who had a negative sputum smear
than amongst people with a positive sputum smear. When all the data
for these different studies were combined, the statistics indicated that
the commercial tests, overall, were only modestly accurate for diagnosis
of TB disease. None of the studies had been carried out in children or in
HIV-positive people.
What Do These Findings Mean? The results of this systematic review
suggest that the commercial antibody detection tests considered here
are not particularly useful in diagnosis of TB disease as compared to
other tests, such as sputum smear and bacterial culture. Some people are
concerned that there is pressure in certain developing countries to start
using these tests, but the current data do not support greater use. This
systematic review also highlights the fact that many studies evaluating
commercial TB tests are of poor quality, and that further research needs
to be done to evaluate the accuracy of different TB tests amongst
children and HIV-positive patients.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040202.
 World Health Organization Stop TB Department website. Information
about the current Stop TB strategy, data and factsheets about TB, and
other resources are available
 Questions and Answers about Tuberculosis provided by the US
Centers for Disease Control and Prevention
 Information about TB tests from Me´dicins sans Frontie`res (MSF). Links
to MSF reports on new diagnostic tests are also available
 Wikipedia entry on Systematic Reviews (Note: Wikipedia is an internet
encyclopedia anyone can edit)
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